Cargando…

PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [(18)F]PF-06684511

PURPOSE: Beta-secretase 1 (BACE1) enzyme is implicated in the pathophysiology of Alzheimer’s disease. [(18)F]PF-06684511 is a positron emission tomography (PET) radioligand for imaging BACE1. Despite favorable brain kinetic properties, the effective dose (ED) of [(18)F]PF-06684511 estimated in non-h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arakawa, Ryosuke, Takano, Akihiro, Stenkrona, Per, Stepanov, Vladimir, Nag, Sangram, Jahan, Mahabuba, Grybäck, Per, Bolin, Martin, Chen, Laigao, Zhang, Lei, He, Ping, Villalobos, Anabella, McCarthy, Timothy J., Halldin, Christer, Varrone, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396399/ https://www.ncbi.nlm.nih.gov/pubmed/32140803 http://dx.doi.org/10.1007/s00259-020-04739-5

Ejemplares similares

Characterization of a Novel M4 PAM PET Radioligand [11C]PF06885190 in Nonhuman Primates (NHP)
por: Nag, Sangram, et al.
Publicado: (2023)

Test-retest reproducibility of [(11)C]-l-deprenyl-D(2) binding to MAO-B in the human brain
por: Arakawa, Ryosuke, et al.
Publicado: (2017)

Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: (18)F-AZD9272
por: Nag, Sangram, et al.
Publicado: (2020)

PET Imaging of VMAT2 with the Novel Radioligand [(18)F]FE-DTBZ-d4 in Nonhuman Primates: Comparison with [(11)C]DTBZ and [(18)F]FE-DTBZ
por: Nag, Sangram, et al.
Publicado: (2021)

Quantification and reliability of [(11)C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung — a test-retest PET study in control subjects
por: Cselényi, Zsolt, et al.
Publicado: (2020)

Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [(18)F]FMeNER-D(2)
por: Arakawa, Ryosuke, et al.
Publicado: (2019)

Kinetic analysis and test-retest variability of the radioligand [(11)C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects
por: Jučaite, Aurelija, et al.
Publicado: (2012)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Target occupancy study and whole-body dosimetry with a MAGL PET ligand [(11)C]PF-06809247 in non-human primates
por: Arakawa, Ryosuke, et al.
Publicado: (2022)

D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients
por: Stenkrona, Per, et al.
Publicado: (2019)

In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [(18)F]FEDAA1106
por: Takano, Akihiro, et al.
Publicado: (2013)

[(11)C]SCH23390 binding to the D(1)-dopamine receptor in the human brain—a comparison of manual and automated methods for image analysis
por: Stenkrona, Per, et al.
Publicado: (2018)

PET Evaluation of the Novel F-18 Labeled Reversible Radioligand [(18)F]GEH200449 for Detection of Monoamine Oxidase-B in the Non-Human Primate Brain
por: Varnäs, Katarina, et al.
Publicado: (2023)

Decreased defluorination using the novel beta-cell imaging agent [(18)F]FE-DTBZ-d4 in pigs examined by PET
por: Jahan, Mahabuba, et al.
Publicado: (2011)

[(18)F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study
por: Kerstens, Vera S., et al.
Publicado: (2023)

Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study
por: Plavén-Sigray, Pontus, et al.
Publicado: (2018)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

PET imaging of [(11)C]PBR28 in Parkinson’s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding
por: Varnäs, Katarina, et al.
Publicado: (2018)

High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson’s disease cohort
por: Fazio, Patrik, et al.
Publicado: (2020)

Potential for imaging the high-affinity state of the 5-HT(1B) receptor: a comparison of three PET radioligands with differing intrinsic activity
por: Lindberg, Anton, et al.
Publicado: (2019)

Development of a Novel [(11)C]CO-Labeled Positron Emission Tomography Radioligand [(11)C]BIO-1819578 for the Detection of O-GlcNAcase Enzyme Activity
por: Nag, Sangram, et al.
Publicado: (2023)

Production of [(11)C]Carbon Labelled Flumazenil and L-Deprenyl Using the iMiDEV™ Automated Microfluidic Radiosynthesizer
por: Mallapura, Hemantha, et al.
Publicado: (2022)

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline
por: Sturm, Stefan, et al.
Publicado: (2016)

Decreased 5‐HT(1A) binding in mild Alzheimer's disease—A positron emission tomography study
por: Mattsson, Patrik, et al.
Publicado: (2022)

Reliability of dopamine transporter PET measurements with [(18)F]FE-PE2I in patients with Parkinson’s disease
por: Kerstens, Vera S., et al.
Publicado: (2020)

Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [(18)F]FE-PE2I-OH for Translational Dopamine Transporter Imaging
por: Schou, Magnus, et al.
Publicado: (2023)

Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
por: Yang, Xuran, et al.
Publicado: (2018)

Biogenesis of γ-secretase early in the secretory pathway
por: Kim, Jinoh, et al.
Publicado: (2007)

GABA(A) receptor occupancy by subtype selective GABA(Aα2,3) modulators: PET studies in humans
por: Jucaite, Aurelija, et al.
Publicado: (2016)

Simplified quantification of [(18)F]FE-PE2I PET in Parkinson’s disease: Discriminative power, test–retest reliability and longitudinal validity during early peak and late pseudo-equilibrium
por: Brumberg, Joachim, et al.
Publicado: (2020)

Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B
por: Nag, Sangram, et al.
Publicado: (2020)

Correction to “Development of (11)C-Labeled ASEM Analogues for Detection of Neuronal Nicotinic Acetylcholine Receptors (α7-nAChR)”
por: Nag, Sangram, et al.
Publicado: (2022)

Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography
por: Arakawa, Ryosuke, et al.
Publicado: (2018)

PET technology for drug development in psychiatry
por: Arakawa, Ryosuke, et al.
Publicado: (2020)

Development of (11)C-Labeled ASEM Analogues for the Detection of Neuronal Nicotinic Acetylcholine Receptors (α7-nAChR)
por: Nag, Sangram, et al.
Publicado: (2022)

Quantification of the purinergic P2X(7) receptor with [(11)C]SMW139 improves through correction for brain-penetrating radiometabolites
por: Brumberg, Joachim, et al.
Publicado: (2022)

Positron Emission Tomography studies with [(11)C]PBR28 in the Healthy Rodent Brain: Validating SUV as an Outcome Measure of Neuroinflammation
por: Tóth, Miklós, et al.
Publicado: (2015)

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer
por: Locatelli, Marzia A., et al.
Publicado: (2016)

Nanoscale organization of Nicastrin, the substrate receptor of the γ-secretase complex, as independent molecular domains
por: Kedia, Shekhar, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I Studies
por: Ahn, Jae Eun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9r42q29cf3fr2dr3c2st9euc55